Wednesday, January 17, 2018

Report: Juno Therapeutics, Celgene In Acquisition Talks

Seattle-based Juno Therapeutics is in talks with Celgene, where Celgene is reportedly looking to acquire Juno, according to the Wall Street Journal. Financial details of the possible deal were not released, and neither company has yet confirmed the activity. Juno Therapeutics has a market cap of around $5.5 billion. The company develops cancer treatments.